Eli Lilly: Positives Outweigh The Concerns

Eli Lilly and Company's price jump following its latest earnings release is completely justified going by both the performance and guidance. Both LLY revenue and EPS growth exceeded guidance, despite a cut in Zepbound's price in Q4 2025. The guidance for 2026 also makes the stock attractive. However, a fuller impact of price cuts is expected to be visible only a quarter later, along with a possible impact of an acquisition on its earnings, indicating some caution is warranted for LLY stock....

Seeking Alpha - 2/5/2026 6:28:36 PM More News for LLY
Stock Analysis for LLY
Related Stocks: